Sweden· SE-20190415000109
Valaciclovir Abacus Medicine 250 mg Filmdragerad tablett
A valaciclovir product, registered in Sweden by Abacus Medicine A/S. The same ATC class is registered in 18 of our 19 countries.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
Where it is registered
Valaciclovir is registered in 18 of 19 countries.
Countries holding a registration under ATC J05AB11 (valaciclovir), each read from that country’s own register.
- This record: Sweden, from Swedish Medical Products Agency (Sweden)
- 11 of them publish a price we can compare per daily dose
Valaciclovir · ATC J05AB11
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of valaciclovir costs, country by country.
Normalised to the WHO defined daily dose (3 g), the median price runs from $1.30 in United States to $12.40 in Switzerland — a ×9.6 gap.
- 5 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Valaciclovir · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$12.40
- IT Italy$9.73
- ES Spain$7.89
- FR France$4.81
- US United States$1.30 (acquisition cost)
The record
At a glance
Swedish Medical Products Agency (Sweden)- Manufacturer
- Abacus Medicine A/S
- Country
- Sweden (SE)
- ATC code
- J05AB11
- ATC class
- Valaciclovir
- Defined daily dose
- 3 g, O
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20190415000109
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
226 interactions on record for valaciclovir.
Graded by severity as the source publishes them — 16 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Valaciclovir · interactions on record
226 records
- 16 severe
- 29 moderate
- 2 minor
- 178 info
Most severe, free to view
- TemsirolimusL01EG01severe
- EverolimusL01EG02severe
- SirolimusL01EG04severe
- TemsirolimusL01XE09severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J05AB11
Valaciclovir, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/909b067e-d77a-42c9-8e7d-047d82529fbc GET /v1/drugs/909b067e-d77a-42c9-8e7d-047d82529fbc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"PL"
],
"se_npl_id": "20190415000109",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20190415000109",
"product_doc_link": "https://docetp.mpa.se/LMF/Valaciclovir%20Abacus%20Medicine%20250%20mg%20film-coated%20tablet%20NL%20PL_09001bee807a6f4f.pdf"
}See everything about valaciclovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.